Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.

about

Pharmacological treatment of diabetes in older people.Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain-Adipocyte Axis.Long-Acting Phospholipid Gel of Exenatide for Long-Term Therapy of Type II Diabetes.

P2860

Q38235153-92007803-D9D5-4E5E-AEFB-D11DA6A3D3C1 Q38753804-BE050DE3-C236-4580-AE34-259274CF865D Q53180223-3ACE9BEB-FDE0-44D6-B33E-A0C562534B5F

P2860

Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.

Item

http://www.wikidata.org/entity/Q38095813

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Once-weekly exenatide: an exte ...... t of type 2 diabetes mellitus.

@en

type

Item

label

Once-weekly exenatide: an exte ...... t of type 2 diabetes mellitus.

@en

prefLabel

Once-weekly exenatide: an exte ...... t of type 2 diabetes mellitus.

@en

P1476

Once-weekly exenatide: an exte ...... t of type 2 diabetes mellitus.

@en

P2093

Kristian Frugé

http://www.w3.org/2001/XMLSchema#string

Mary S Klein

http://www.w3.org/2001/XMLSchema#string

Michelle J Jernigan

http://www.w3.org/2001/XMLSchema#string

Molly G Minze

http://www.w3.org/2001/XMLSchema#string

Stephen L Wise

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years.

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

Incretin-based therapies for type 2 diabetes mellitus.

Management of type 2 diabetes: new and future developments in treatment.

P304

627-638

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PHAR.1240

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23553357

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.

about

P2860

P2860

Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921